Therapeutic Antibodies

#Biologics #CAR-T #Cell and gene therapy #Cell therapy #PCR #Whitepaper

Whitepaper on digital PCR for lentiviral vector characterisation

A new Whitepaper is available from Thermo Fisher Scientific, entitled ‘Lentiviral vector characterization for cell and gene therapy manufacturing using the QuantStudio Absolute Q Digital PCR System’. Recombinant lentiviral vectors are used for ex vivo transgene delivery in several gene-modified cell therapies, such as chimeric antigen receptor (CAR) T cell therapy. Read More

#News

#Biologics #CAR-T #Cell and gene therapy #Cell therapy #PCR

Explore the power of digital PCR for lentiviral vector characterisation

Recombinant lentiviral vectors are used for ex vivo transgene delivery in several gene-modified cell therapies, such as chimeric antigen receptor (CAR) T cell therapy. Reliable analytical methods such as digital PCR to characterise lentiviral vectors and the cells transduced with them are critical to helping ensure the safety and efficacy of… Read More

#Resources

FDA
#Bispecific Antibodies #FDA #Janssen #Myeloma #Oncology

Janssen myeloma drug approved in US via a restricted programme

The FDA has granted accelerated approval to Janssen’s talquetamab-tgvs (Talvey) for adults with relapsed or refractory multiple myeloma. It has been approved in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Talquetamab is a bispecific… Read More

#News #Regulatory

Antibodies
#Antibodies #Collaboration #Funding #Infectious diseases #LifeArc #Liverpool School of Tropical Medicine

Infectious diseases research fund will progress antibody therapies

Liverpool School of Tropical Medicine (LSTM) and LifeArc are partnering to launch a new Translational Development Fund to help tackle infectious diseases. LifeArc will invest £2.7 ($3.4) million into the fund, which will support the progression of new technologies and treatments for emerging viral threats and… Read More

#News

CAR-T therapy
#Aleta Biotherapeutics #Biologics #Cancer research #Cancer Research UK #CAR-T #MHRA #Oncology

Biologic CAR-T cell engager approved for UK clinical trial

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Aleta Biotherapeutics a clinical trial authorisation (CTA) to evaluate biologic ALETA-001 in a Phase I/II clinical trial in patients with B-cell malignancies who are relapsed/refractory to CD19 CAR-T cell therapy. The company’s collaboration partner, Cancer Research UK’s Centre for… Read More

#Cancer Research #News #Regulatory

#Biologics #Collaboration #Ginkgo Bioworks #Merck

Ginkgo and Merck collaborate to improve biologic manufacturing 

Ginkgo Bioworks and Merck have collaborated to improve the production of biologics.  Ginkgo will apply its expertise and capabilities in cell engineering, ultra high-throughput multiplexed screening, protein characterisation and process optimisation to improve production efficiency and increase yields.   “We’re thrilled to leverage our platform to… Read More

#News

#Antibodies #Bispecific Antibodies #Cancer research #CHMP #Oncology

DDW Highlights: 7 August 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The pace of innovation in cancer drug discovery showed no signs of slowing… Read More

#News

#Antibodies #Bispecific Antibodies #Cancer research #CHMP #Oncology

This week in drug discovery (31 July – 4 August)  

News round-up for 31 July – 4 August by DDW Digital Content Editor Diana Spencer. The pace of innovation in cancer drug discovery showed no signs of slowing this week, with several pretty momentous discoveries boosting research in the sector. These include the creation of a… Read More

#News

Neuroblastoma
#Cancer research #Monoclonal antibodies #Neuroscience #Oncology #Phase II trial #Renaissance Pharma

Renaissance Pharma licenses Hu14.18 for neuroblastoma

Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. Fifty percent of neuroblastoma patients have high-risk (HRNB) disease which has an overall survival… Read More

#Cancer Research #News

#Antibodies #Bispecific Antibodies #Cancer research #CHMP #Oncology

New podcast episode: DDW Highlights 31 July 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  To coincide with the publication of the DDW eBook ‘Antibody discovery:… Read More

#News

#Antibodies #Bispecific Antibodies #Cancer research #CHMP #Oncology

This week in drug discovery (24-28 July)  

News round-up for 24-28 July by DDW Digital Content Editor Diana Spencer. To coincide with the publication of the DDW eBook ‘Antibody discovery: Breakthroughs accelerating therapeutic antibodies’, our news highlights this week all focus on antibodies, particularly the recommendation by the EU’s CHMP… Read More

#News

Biologics research
#Biologics #Drug development #Drug discovery #Guide #Monoclonal antibodies #Screening

Guide: Assessing thermal stability with nanoDSF

A new Guide ‘The biologics researcher’s mini-guide to screening candidates with nanoDSF’ is now available from NanoTemper. Among the most common critical quality attributes (CQAs) for early developability assessment is thermal stability. One particular tool for assessing thermal stability with high resolution is nano-differential scanning fluorimetry (nanoDSF). Read More

#News

#Biologics #Drug development #Drug discovery #Guide #Monoclonal antibodies #Screening

The biologics researcher’s mini-guide to screening candidates with nanoDSF

Among the most common critical quality attributes (CQAs) for early developability assessment is thermal stability. One particular tool for assessing thermal stability with high resolution is nano-differential scanning fluorimetry (nanoDSF). Read this mini-guide to learn: How nanoDSF uses your protein’s intrinsic fluorescence to determine its melting temperature, Tm and onset… Read More

#Intelligence #Resources

Antibodies
#Antibodies #Drug discovery #eBook

eBook: Breakthroughs accelerating therapeutic antibodies

The latest eBook by DDW is out now. This 24-page eBook sponsored by Carterra examines the market for therapeutic antibodies and the breakthroughs driving drug discovery in this sector. Download this exclusive eBook to learn more about: The market for therapeutic antibodies Advancements and challenges in the sector Trends… Read More

#News

Bispecific antibodies
#AbbVie #Bispecific Antibodies #Cancer research #CHMP #EMA #Genmab #Haematology #Oncology

Bispecific antibody a “promising treatment option” for DLBCL

The EU Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of conditional marketing authorisation for epcoritamab (Tepkinly) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The final… Read More

#News #Regulatory

Multiple myeloma
#Bispecific Antibodies #Cancer research #CHMP #EMA #Janssen #Myeloma #Oncology

CHMP recommendation for bispecific antibody talquetamab

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional marketing authorisation for Janssen’s Talvey (talquetamab). The drug has received a positive opinion for use as a monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who… Read More

#News #Regulatory